Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

85.00EUR
18 May 2018
Change (% chg)

€-1.04 (-1.21%)
Prev Close
€86.04
Open
€86.00
Day's High
€86.00
Day's Low
€84.74
Volume
801,348
Avg. Vol
629,680
52-wk High
€112.65
52-wk Low
€74.54

Chart for

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.03
Market Cap(Mil.): €11,133.13
Shares Outstanding(Mil.): 129.24
Dividend: 1.25
Yield (%): 1.47

Financials

  MRCG.DE Industry Sector
P/E (TTM): 15.29 28.57 32.53
EPS (TTM): 5.56 -- --
ROI: 8.75 13.08 12.63
ROE: 17.49 14.80 14.50

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find a drug-industry partner to share further development costs for one of them.

May 17 2018

UPDATE 2-Merck KGaA's lung cancer drugs show promise in early-stage trials

* Shares up 5.2 pct (Adds Merck ruling out enlisting partner for tepotinib development)

May 17 2018

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT, May 16 Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping the company's efforts to find drug-industry partners to share further development costs.

May 16 2018

Merck KGaA first quarter earnings down on liquid crystals, currencies

FRANKFURT Germany's Merck KGaA saw earnings decline in the first quarter and predicted a drop for the full year, hurt by Chinese competition in liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

May 15 2018

UPDATE 1-Merck KGaA Q1 earnings down on liquid crystals, currencies

* Strong euro to cause 5-7 percent drag on 2018 EBITDA (Adds detailed guidance, forex effects)

May 15 2018

Merck KGaA Q1 earnings down on liquid crystals, currencies

FRANKFURT, May 15 Germany's Merck KGaA saw earnings decline in the first quarter, hurt by Chinese competition in liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

May 15 2018

Setback to Roche hopes for Tecentriq as fails key cancer trial

ZURICH Roche's hopes of its Tecentriq immunotherapy catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.

May 10 2018

Merck KGaA family says unreservedly behind the pharma unit

DARMSTADT, Germany The family behind Germany's Merck KGaA said it was fully committed to the diversified group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales.

May 03 2018

UPDATE 1-Merck KGaA family says unreservedly behind the pharma unit

* Family backs pharma unit even if avelumab not a blockbuster

May 03 2018

Merck KGaA family says unreservedly behind the pharma unit

DARMSTADT, Germany, May 3 The family behind Germany's Merck KGaA said it was fully committed to the group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales.

May 03 2018

Earnings vs. Estimates